Centre for Cancer Biomarkers CCBIO
CCBIO Seminar series

CCBIO Seminar – Therese Sørlie

Welcome to the CCBIO seminars in the spring term 2022. Open to all in Zoom. Speaker is Therese Sørlie, Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo.

Main content

Speaker: Therese Sørlie, Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo

Bio: Therese Sørlie is the Head of department of Cancer Genetics and Professor II at the Institute of Clinical Medicine, University of Oslo. Her research field is breast cancer, DCIS and risk prediction. Dr. Sørlie was instrumental in the pioneering studies that defined the molecular subtypes of breast cancer, now part of clinically approved classification systems. Since then her studies focus on progression in the earliest stages of tumorigenesis under the hypothesis that progression occurs differently among the different subtypes. Recently, Dr Sørlie’s group has focused on a subgroup of hormone receptor positive breast cancer, namely FGFR1 amplified luminal A and B breast cancer. In the seminar she will discuss how FGFR1 might be a therapeutic target in FGFR1–signalling dependent tumors and may reverse endocrine resistance. She will also briefly present current efforts to study spatial heterogeneity in DCIS. 

Title of the talk: “FGFR1 as a biomarker and target for therapy in hormone receptor positive breast cancer”

Abstract: Luminal breast cancer (expressing estrogen receptor and/or progesterone receptor) accounts for approximately 75% of all breast cancers tumors and are associated with relatively good survival due to efficient treatment with endocrine therapy.  Despite this, a significant proportion (up to 40 %) will in the longer term, develop resistance to therapy and disease recurrence. Many different growth factor receptors and signaling pathways are involved in breast cancer development and progression and in development of resistance. One such growth factor receptor, Fibroblast growth factor receptor 1 (FGFR1), is amplified in up to 27% of luminal cancers (highest in luminal B subtype) and is an independent prognostic marker associated with short overall survival rates. In this seminar, I will discuss our ongoing project on FGFR1 and its potential as a biomarker and target for therapy in luminal breast cancer. Through in vitro and in vivo experiments, we have shown that targeting FGFR1 inhibits cell proliferation and slows down tumor growth and may also re-sensitize resistant cells to hormone treatment. 

Time: April 28, 2022 at 13.00

Place: Digital through Zoom. Access link as audience: https://uib.zoom.us/j/66717563083?pwd=aEp1SnRFZ0w3MGJ2M3RBWm1vMXBodz09
If asked for passcode, use: t7NpVSYz

Host: Lars A. Akslen

Zoom practicalities:

Note: Please change any username to your name when logging in, so that chair can address you by name if you have questions.

  • Your sound and video will be turned off as default for security reasons, and only host can de-mute individual participants.
  • We will open for questions after the lecture, where you can use the Raise hand function, or type your question in Chat. Host will then de-mute your sound and address you by your name (please log on with your name).
  • If you think you might want to ask questions, please test your microphone beforehand. Make sure your microphone is turned on. (Or ask host to read out your typed question).
  • We advise all to have a Zoom account on your device beforehand (free service), that will save you some minutes when logging on.

Those of us with University of Bergen (UiB) client machines, might already have Zoom. If not, see https://it.uib.no/Jeg_skal_bruke_Zoom_for_f%C3%B8rste_gang

For private machines (not UiB), see https://zoom.us/download#client_4meeting   Otherwise, clicking the logon link provided above will prompt the Zoom app to download, but it saves you time to have done this beforehand.